Suppr超能文献

针对肝硬化患者肝细胞癌的多学科治疗方法。

A multidisciplinary approach to hepatocellular carcinoma in patients with cirrhosis.

作者信息

Schwartz M E, Sung M, Mor E, Fisher A, Popescu I, Fiel I, Sheiner P, Emre S, Guy S, Miller C M

机构信息

Department of Surgery, Mount Sinai Medical Center, New York, NY 10029, USA.

出版信息

J Am Coll Surg. 1995 May;180(5):596-603.

PMID:7749537
Abstract

BACKGROUND

A multidisciplinary approach has been developed to evaluate and treat patients with cirrhosis and hepatocellular carcinoma (HCC).

STUDY DESIGN

We evaluated 153 patients with cirrhosis and HCC. Fourteen patients with Child's A cirrhosis underwent resection. Transplantation was performed in 40 patients with HCC less than 5 cm (32 incidental, eight recognized preoperatively), in six patients with HCC 5 cm or greater not recognized preoperatively, and in 11 patients with recognized HCC 5 cm or greater; the latter 11 underwent transplantation in a multimodality protocol using pretransplant chemoembolization and intraoperative and postoperative chemotherapy.

RESULTS

Among the 14 patients who underwent resection, the three-year survival rate was 39 percent. Among the 40 patients with HCC less than 5 cm who underwent transplantation, no tumor recurrence was observed. Among the six with HCC 5 cm or greater unrecognized preoperatively, three had tumor recurrence. Among the 11 with HCC 5 cm or greater enrolled in the protocol, there were no deaths and one recurrence at a mean of 433 days follow-up. The four-year survival rate for all patients who underwent transplantation with HCC was 56 percent (66 percent excluding the six patients with unrecognized HCC 5 cm or larger).

CONCLUSIONS

Hepatocellular carcinoma less than 5 cm in patients with cirrhosis (Child's B or C) is an indication for hepatic transplantation. Hepatocellular carcinoma less than 5 cm in patients with cirrhosis (Child's A), although resectable, may in some cases be better treated by hepatic transplantation. Transplantation for HCC 5 cm or greater within a multimodality protocol has yielded excellent results at two years.

摘要

背景

已开发出一种多学科方法来评估和治疗肝硬化和肝细胞癌(HCC)患者。

研究设计

我们评估了153例肝硬化和HCC患者。14例Child's A级肝硬化患者接受了切除术。40例HCC小于5 cm的患者接受了移植(32例为意外发现,8例术前已确诊),6例术前未确诊的HCC 5 cm或更大的患者,以及11例已确诊的HCC 5 cm或更大的患者接受了移植;后11例患者在多模式方案中接受移植,该方案使用移植前化疗栓塞以及术中及术后化疗。

结果

在接受切除术的14例患者中,三年生存率为39%。在接受移植的40例HCC小于5 cm的患者中,未观察到肿瘤复发。在6例术前未确诊的HCC 5 cm或更大的患者中,3例出现肿瘤复发。在纳入该方案的11例HCC 5 cm或更大的患者中,平均随访433天无死亡病例,1例复发。所有接受HCC移植患者的四年生存率为56%(不包括6例未确诊的HCC 5 cm或更大的患者为66%)。

结论

肝硬化(Child's B或C级)患者中HCC小于5 cm是肝移植的指征。肝硬化(Child's A级)患者中HCC小于5 cm,尽管可切除,但在某些情况下肝移植可能是更好的治疗方法。在多模式方案中对HCC 5 cm或更大的患者进行移植,两年时已取得了优异的结果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验